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Abstract
Background: Network meta-analyses using individual participant data (IPD-NMAs) have been increasingly used to
compare the effects of multiple interventions. Although there have been many studies on statistical methods for
IPD-NMAs, it is unclear whether there are statistical defects in published IPD-NMAs and whether the reporting of
statistical analyses has improved. This study aimed to investigate statistical methods used and assess the reporting
and methodological quality of IPD-NMAs.
Methods: We searched four bibliographic databases to identify published IPD-NMAs. The methodological quality
was assessed using AMSTAR-2 and reporting quality assessed based on PRISMA-IPD and PRISMA-NMA. We
performed stratified analyses and correlation analyses to explore the factors that might affect quality.
Results: We identified 21 IPD-NMAs. Only 23.8% of the included IPD-NMAs reported statistical techniques used for
missing participant data, 42.9% assessed the consistency, and none assessed the transitivity. None of the included
IPD-NMAs reported sources of funding for trials included, only 9.5% stated pre-registration of protocols, and 28.6%
assessed the risk of bias in individual studies. For reporting quality, compliance rates were lower than 50.0% for
more than half of the items. Less than 15.0% of the IPD-NMAs reported data integrity, presented the network
geometry, or clarified risk of bias across studies. IPD-NMAs with statistical or epidemiological authors often better
assessed the inconsistency (P = 0.017). IPD-NMAs with a priori protocol were associated with higher reporting
quality in terms of search (P = 0.046), data collection process (P = 0.031), and syntheses of results (P = 0.006).
Conclusions: The reporting of statistical methods and compliance rates of methodological and reporting items of
IPD-NMAs were suboptimal. Authors of future IPD-NMAs should address the identified flaws and strictly adhere to
methodological and reporting guidelines.
Keywords: Network meta-analysis, Individual participant data, Statistical analysis, Methodological quality, Reporting
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Background
Meta-analysis based on individual participant data (IPD)
from randomized controlled trials (RCTs) [1, 2] is con-
sidered the “gold standard” of meta-analyses. The use of
IPD in meta-analysis offers more flexibility in the inves-
tigation of patient-level moderators [3], allows the
standardization of outcome definitions and analyses
across studies [4, 5], and helps improve the quantity and
quality of data [6–8]. Network meta-analysis (NMA),
also known as mixed treatment comparison or multiple
treatments comparison meta-analysis, is a statistical
method to directly and indirectly compare the effects of
two or more treatments and allows ranking of different
treatments [9–12]. Although NMAs usually include ag-
gregate data from RCTs [13], there are many advantages
to incorporating IPD into NMAs, including more appro-
priate investigation of heterogeneity or inconsistency by
using advanced modeling strategies to explore subject-
level covariates [14–16], and identifying interactions of
patient-level effect modifiers [17–19].
Previous studies have evaluated the statistical methods,
methodological and reporting characteristics of IPD
meta-analyses [2, 20]. A comprehensive scoping review
found that indirect comparisons using IPD often failed
to report key statistical methods [3], which may lead to
biased conclusions. Several studies also assessed the
methodological quality and the conduct of published
NMAs [21–25]. But no studies have focused solely on
the reporting and methodological quality of IPD-NMAs.
Researchers have recognized that the use of IPD in
NMAs may yield the most trustworthy evidence to in-
form clinical decision-making [26]. However, when IPD-
NMAs have methodological flaws, they could threaten
the validity of the results and thus mislead clinical
decision-making [16, 27]. Although there have been
many studies on statistical methods for IPD-NMAs [26,
28, 29], it is unclear whether there are statistical defects
in published IPD-NMAs and whether the reporting of
statistical analyses has improved.
The objectives of this study were to explore the gen-
eral characteristics, statistical analysis methods used,
reporting quality, and methodological quality of IPD-
NMAs and to identify study-level variables that were as-
sociated with the methodological and reporting quality.
Methods
Literature search
A comprehensive literature search was conducted on
PubMed, Embase.com, Cochrane Library, and Web of
Science using the following items: “network meta-
analysis”, “mixed treatment comparison meta-analysis”,
“mixed treatment meta-analysis”, “multiple treatment
comparison meta-analysis”, “multiple treatment meta-
analysis”, “indirect comparison”, “individual patient”,
“individual participant”, and “patient level”. The detailed
search strategy of PubMed is presented in Add-
itional file 1: Appendix Word 1. We performed the ini-
tial search on December 13, 2018, and updated the
search on June 3, 2019. We also manually retrieved ref-
erences of included IPD-NMAs and relevant reviews.
Eligibility criteria
Because NMAs using IPD from RCTs provide the most
valid results, we included IPD-NMAs of RCTs that eval-
uated the clinical effects of three or more interventions
for patients in any clinical conditions. There were no re-
strictions on publication year and language.
Studies including the following were excluded: (1)
NMAs did not incorporate IPD; (2) pairwise meta-
analyses of IPD; (3) IPD-NMAs did not focus on health
care interventions such as etiology and diagnosis; (4)
studies that only applied simulated treatment compari-
son [30], adjusted indirect comparisons [31], or match-
ing adjusted indirect comparisons (MAICs) [32] failing
to preserve within-study randomization; and (5) meth-
odological studies, review protocols, abstracts, confer-
ence proceedings, and letters to editors.
Study selection
We used EndNote X8 (Thomson Reuters (Scientific)
LLC Philadelphia, PA, USA) to manage the retrieved re-
cords. Two review authors (Y.G. and S.Z.S.) independ-
ently reviewed titles and abstracts identified through the
electronic search. Full reports of any potentially relevant
papers were retrieved for further assessment of eligibil-
ity. If an IPD-NMA has been updated, we would only in-
clude the latest version. Differences of opinion were
settled by consensus or referral to a third review author
(F.J.S. or J.H.T.).
Data extraction
We developed a data extraction form using Microsoft
Excel 2016 (Microsoft Corp, Redmond, WA, www.
microsoft.com) to abstract data on general characteris-
tics and statistical analysis methods used, including pub-
lication year, first author, country of corresponding
authors, number of authors, journal name, whether a
statistician or epidemiologist (based on the author’s
current academic position) was involved, whether IPD-
NMAs had a priori protocol, funding source (industry,
non-industry, unfunded, or not reported), the topic of
interest, number of trials included, number of partici-
pants included, number of interventions included, for-
mat of data included in analysis (individual participant
data, aggregate data), whether used Bayesian method or
Frequentist method, 1-stage or 2-stage process, statis-
tical techniques used for missing data, methods used to
assess heterogeneity, and methods used to assess
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consistency and transitivity. We piloted the data extrac-
tion on a random sample of five included studies and
achieved consistency in data item interpretations. Then,
four trained authors (Y.G., S.Z.S., M.Y.L., and X.Y.L.) ab-
stracted data from the included IPD-NMAs, and another
two reviewers (J.H.Z. and J.H.T.) checked the data. Dis-
agreements were resolved by discussion.
Reporting and methodological quality assessment
The reporting quality of the included IPD-NMAs was
evaluated according to the Preferred Reporting Items for
Systematic Review and Meta-Analyses of individual par-
ticipant data (PRISMA-IPD) statement, which is a
checklist of 31 items aimed to improve the completeness
and transparency of reporting of systematic reviews
(SRs) and meta-analyses of individual participant data
[1]. To identify the important information that should
be reported in a network meta-analysis, we also applied
five supplemental items of Preferred Reporting Items for
Systematic Reviews and Meta-analyses extension
(PRISMA-NMA) statement (S1. Geometry of the net-
work, S2. Assessment of inconsistency, S3. Presentation
of network structure, S4. Summary of network geometry,
S5. Exploration for inconsistency) [33]. Each item was
rated with “yes” (total compliance), “partial” (partial
compliance), or “no” (noncompliance) [24, 34].
We used the Assessment of Multiple Systematic
Reviews-2 (AMSTAR-2) tool to assess the methodo-
logical quality of the included IPD-NMAs [35]. This tool
assesses the methodological quality of SRs across 16 do-
mains, among which seven are critical [35]. Each domain
can be rated as “yes” (item fully addressed), “no” (item
not addressed), or “partial yes” (item not fully ad-
dressed). According to the critical domains, the overall
confidence of the quality of each review can be classified
as high, moderate, low, or critically low [35]. The quality
assessment was conducted by one reviewer (Y.G., S.Z.S.,
M.Y.L., and X.Y.L.) and verified by another. Possible dis-
agreements were resolved by consensus or with the con-
sultation of a third party (F.J.S. or J.H.T.).
Data analysis
We applied frequency and percentage to present cat-
egorical variables and median and interquartile range
(IQR) to present continuous variables. For individual
items of reporting and methodological quality, the com-
pliance rate was computed with the number of items
acquired “yes” and the total number of the included
IPD-NMAs. Then, we created Radar maps and bubble
plots using Microsoft Excel 2016 (Microsoft Corp, Red-
mond, WA, www.microsoft.com) to present the compli-
ance rates. We classified the included IPD-NMAs
according to the following characteristics: with or with-
out a statistician or epidemiologist, with or without a
priori protocol, non-industry or industry funding, using
a Bayesian or a Frequentist method, and using the 1-
stage process or the 2-stage process. We then performed
Fisher’s exact test to compare the compliance of each
PRISMA-IPD, PRISMA-NMA, and AMSTAR-2 item by
the above characteristics. The analyses were conducted
in Stata (13.0; Stata Corporation, College Station, Texas,
USA), and the statistical level of significance was set at
P < 0.05.
To investigate whether the reporting quality was asso-
ciated with the methodological quality of IPD-NMAs,
we also performed the correlation analysis. We
computed the number of items acquired “yes” of
PRISMA-IPD and AMSTAR-2 for each IPD-NMA.
Then, we conducted the Shapiro-Wilk test and created
the Q-Q normal map to evaluate the normality of num-
bers of items acquired “yes” of PRISMA-IPD and
AMSTAR-2 [22, 24], and results indicated that they were
normally distributed (Additional file 1: Appendix Word
2). Therefore, we performed the Pearson correlation
analysis using Stata (13.0; Stata Corporation, College
Station, Texas, USA) to explore the relationship between
fully reported PRISMA-IPD items and AMSTAR-2
items.
Results
Literature search
The search of electronic databases yielded 1376 records,
and we identified five additional records through manu-
ally checking the references of relevant reviews. After re-
moving duplicates and screening titles and abstracts, we
identified 107 reports for the full-text assessment. We
further excluded 9 aggregate NMAs, 39 MAICs, 6 indir-
ect comparisons, 31 methodological studies, and 1 IPD
meta-analysis. Eventually, there were 21 IPD-NMAs that
met our eligibility criteria (Fig. 1). A list of the included
IPD-NMAs is shown in Additional file 1: Appendix
Word 3.
General characteristics of included IPD-NMAs
The first IPD-NMA was published in 2007, and the
remaining were all published since 2010. The USA (9,
42.9%) published the largest number of IPD-NMAs,
followed by the UK (7, 33.3%) and France (3, 14.3%). A
wide range of different diseases was studied in the in-
cluded IPD-NMAs (Fig. 2). All the 21 IPD-NMAs were
conducted by four or more authors, including eight IPD-
NMAs that involved 11 or more authors. Seven (33.3%)
IPD-NMAs had statistical or epidemiological authors
and 6 (28.6%) IPD-NMAs had a priori protocol. These
IPD-NMAs included a median of 19 RCTs, a median of
7110 participants, and evaluated a median of six inter-
ventions. The details of the general characteristics are
presented in Table 1.
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IPD identification process of included IPD-NMAs
IPD were obtained by forming collaborative research
groups in 12 (57.1%) of the included IPD-NMAs, and
the collection of IPD was by contacting authors of rele-
vant studies identified through SRs in 7 (33.3%) IPD-
NMAs. Three IPD-NMAs reported the proportion of
contacted authors who provided IPD, which ranged from
46.8% to 80.0%. IPD-NMAs that identified relevant trials
through SRs conducted the literature search, and the
commonly used databases were PubMed/MEDLINE,
Cochrane Library, and ClinicalTrials.gov (Table 2).
Reporting of statistical analyses of included IPD-NMAs
Table 3 shows the methods of statistical analyses used
in the included IPD-NMAs. Fourteen (66.7%) IPD-
NMAs used the 1-stage process, and 7 (33.3%) ap-
plied the 2-stage process. Twelve (57.1%) IPD-NMAs
used a Bayesian method, of which 11 synthesized data
using the 1-stage process, and nine (42.9%) used a
Frequentist method, of which 6 adopted the 2-stage
process. Of the 11 IPD-NMAs included only IPD, 6
applied the Bayesian method, and of the 10 IPD-
NMAs incorporated both IPD and aggregate data, 4
applied the Frequentist method. None of the IPD-
NMAs clarified the detailed method used for combin-
ing IPD with aggregate data. Of the 12 Bayesian IPD-
NMAs, all assessed the fit of the model used in data
analysis and deviance information criterion (DIC) was
the most commonly used method, four did not report
the information on the prior distribution, five used
the noninformative prior, one used the informative
prior, and two adopted the noninformative prior and
informative prior. Majority (76.2%) of the IPD-NMAs
simply ignored the missing data, three studies
adopted the last observation carried forward (LOCF)
to handle the missing data, one used the available
case analysis (ACA) method, and one used the Mar-
kov chain Monte Carlo (MCMC) multiple imputations
method. Heterogeneity was assessed in 15 (71.4%)
IPD-NMAs, and subgroup analysis and sensitivity ana-
lysis were the commonly used methods to explore the
sources of heterogeneity. However, only nine IPD-
Fig. 1 The flowchart of the screening process. AD-NMAs, aggregate data network meta-analyses; MAICs, matching adjusted indirect comparisons;
IPD-MAs, individual patient data meta-analyses; IPD-NMAs, individual patient data network meta-analyses
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NMAs evaluated the consistency between direct and
indirect evidence and none assessed the transitivity.
Reporting quality of included IPD-NMAs
In terms of the four PRISMA-IPD additional items, the
rate of full compliance was 81.0%, 52.4%, 38.1%, and
14.3%, respectively, for implication, exploration of vari-
ation, clarification of the IPD integrity in the “Methods”
section, and present it in the “Results” section. Regarding
the five PRISMA-NMA supplemental items, one item
(S3. Presentation of network structure) was fully re-
ported in 57.1% of the IPD-NMAs. However, only 14.3%
of the IPD-NMAs described the geometry of network in
the “Methods” section and summarized the network
geometry in the “Results” section (Fig. 3). Of the
remaining 27 items of PRISMA-IPD, the compliance
rates of 8 items were higher than 75.0%, and two items
(item 3: Rationale, item 26: Conclusions) obtained com-
pliance rates of 100.0%. However, 11 items were not
reported in more than 60.0% IPD-NMAs, and 2 items
(item 5: Protocol and registration, item 15: Risk of bias
across studies) were only presented in 9.5% of the IPD-
NMAs (Additional file 2: Appendix Fig. 1).
IPD-NMAs with a statistician or epidemiologist had a
significantly higher rate in reporting exploration for in-
consistency (71.4% vs. 14.3%) than other IPD-NMAs. A
priori protocol was significantly associated with report-
ing quality in terms of “search” (88.3% vs. 26.7%), “data
collection process” (66.7% vs. 13.3%), and “results of syn-
theses” (83.3% vs. 13.3%). Except for a significant associ-
ation between the 1-stage process and “data items,” no
statistically significant differences were observed be-
tween the reporting quality and other factors, including
industry funding or not, and Bayesian or Frequentist
method (Additional file 1: Appendix Table 1). Improve-
ments were observed in the overall reporting quality
(compliance rates of sixteen PRISMA-IPD items and five
PRISMA-NMA supplemental items have increased) after
Fig. 2 Disease categories of included IPD-NMAs (according to ICD-11). Not applicable if the topic of included SRs does not focus on diseases,
such as the dual antiplatelet therapy after drug-eluting stent implantation
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Table 1 Characteristics of included IPD-NMAs
Items Frequency Proportion (%)
Publication year
2007 1 4.8
2010 1 4.8
2011 1 4.8
2012 5 23.8
2013 1 4.8
2014 4 19.0
2015 2 9.5
2017 3 14.3
2018 2 9.5
2019 1 4.8
Country of the
correspondence author
USA 9 42.9
UK 7 33.3
France 3 14.3
Cameroon 1 4.8
Netherland 1 4.8
Journal impact factor
0.0 to 3.0 6 28.6
3.1 to 6.0 5 23.8
6.1 to 15.0 2 9.5
> 15.0 6 28.6
Non-SCI 2 9.5
Number of authors
1 to 3 authors 0 0
4 to 6 authors 8 38.1
7 to 10 authors 5 23.8
11 or more authors 8 38.1
With statistician or
epidemiologist
7 33.3
Authors from 2 or
more countries
15 71.4
With a priori protocol 6 28.6
Format of data
IPD only 11 52.4
IPD + AD 10 47.6
Number of RCTs included:
median (IQR)
19 (9, 26)
Number of samples included:
median (IQR)
7110 (4906.5, 14261)
Number of interventions included:
median (IQR)
6 (4,7)
Funding sources
Industry 6 28.6
Non-industry 11 52.4
Table 1 Characteristics of included IPD-NMAs (Continued)
Items Frequency Proportion (%)
Industry + non-industry 3 14.3
Unfunded 1 4.8
SCI science citation index, IPD individual participant data, AD aggregate data,
IQR interquartile range
Table 2 IPD identification process of included IPD-NMAs
Items Frequency Proportion
(%)
Methods used to identify IPD eligible studies (n = 21)
Collaborative groupa 12 57.1
Systematic review and contacting
authors
7 33.3
Other methodsb 2 9.5
Did the authors obtain IPD from all studies or just a subset? (n = 21)
All studies 7 33.3
Not reported 14 66.7
IPD-NMAs that identified IPD through systematic reviews (n = 7)
Proportion of contacted authors provided IPD
46.8% 1 14.3
70.0% 1 14.3
80.0% 1 14.3
Not reported 4 57.1
Whether a literature search was
conducted? (yes)
7 100.0
Number of databases searched
2 to 5 3 42.9
6 to 9 3 42.9
14 1 14.3
Name of database
PubMed/MEDLINE 6 85.7
Cochrane Library 6 85.7
ClinicalTrials.gov 6 85.7
EMBASE 4 57.1
Web of Science 2 28.6
ICRTP 2 28.6
Reported the year of retrieval of
databases
6 85.7
Presented search strategy 3 42.9
Online supplement 1 14.3
Manuscript 1 14.3
Previous published study 1 14.3
IPD individual participant data, IPD-NMAs individual participant data network
meta-analyses, ICRTP World Health Organization International Clinical Trials
Registry Platform
aIPD-NMAs project team included authors of IPD studies
bOther methods mean obtaining IPD from the Yale Open Data Access Project
and a previous meta-analysis
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the publication of PRISMA-IPD and PRISMA-NMA
checklists (Additional file 1: Appendix Table 2).
Methodological quality of included IPD-NMAs
Of the 21 IPD-NMAs, one was rated as high quality, one
was classified as low quality, and the remaining nineteen
were rated as critically low quality. Figure 4 shows the
compliance rate of each AMSTAR-2 item. 85.7% of the
IPD-NMAs clarified the components of PICO (popula-
tion, intervention, comparison, and outcome) in the re-
search question and inclusion criteria sections and
71.4% of the IPD-NMAs used appropriate methods
(used an appropriate weighted technique, including the
1-stage or 2-stage, fixed- or random-effects model, and
effect measures to combine study results, and investi-
gated the causes of the heterogeneity) for the statistical
combination of results. However, none of the IPD-
NMAs reported the sources of funding for the studies
included in the review, only two of the 21 IPD-NMAs
pre-specified the review methods and justified the
Table 3 Reporting information of statistical analyses of included
IPD-NMAs
Items Frequency Proportion
(%)
Fixed- or random-effects?
Fixed-effects 6 28.6
Random-effects 6 28.6
Fixed- and random-effects 6 28.6
Not reported 3 14.3
Bayesian or Frequentist method?
Bayesian 12 57.1
Frequentist 9 42.9
1-stage or 2-stage process?
1-stage 14 66.7
2-stage 7 33.3
How was the model fit assessed?
Deviance information criterion 8 38.1
Deviance information criterion + residual
deviance
2 9.5
Not reported 2 9.5
Not applicable 9 42.9
Were the prior distributions reported?
Yes 8 38.1
Noninformative priora 5 23.8
Informative priora 1 4.8
Noninformative prior + informative prior 2 9.5
Not reported 4 19
Not applicable 9 42.9
Was the convergence assessed?
Yes 8 38.1
Gelman-Rubin statistic 4 19
Visual plot inspection 1 4.8
Gelman-Rubin statistic + visual plot
inspection
3 14.3
Not reported 4 19
Not applicable 9 42.9
Statistical techniques used for missing participant data
LOCF 3 14.3
ACA 1 4.8
MCMC multiple imputations 1 4.8
Not reported 16 76.2
Was the heterogeneity assessed?
Yes 15 71.4
Not reported 6 28.6
Was the consistency assessed?
Yes 9 42.9
Loop-specific approach 2 9.5
Table 3 Reporting information of statistical analyses of included
IPD-NMAs (Continued)
Items Frequency Proportion
(%)
Node-splitting 2 9.5
Lu and Ades 1 4.8
Lumley 1 4.8
Informal approachesb 3 14.3
Not reported 12 57.1
Was the transitivity assessed? (yes) 0 0
Subgroup analysis conducted? (yes) 10 47.6
Sensitivity analysis conducted? (yes) 16 76.2
Meta-regression analysis conducted? (yes) 8 38.1
With GRADE used 2 9.5
Software used
WinBUGS/OpenBUGS 7 33.3
R 3 14.3
WinBUGS + R 3 14.3
WinBUGS + Stata 1 4.8
SAS + Review Managerc 2 9.5
SAS + Stata 1 4.8
R + Stata 1 4.8
Not reported 3 14.3
IPD-NMAs individual participant data network meta-analyses, LOCF last
observation carried forward, ACA available case analysis, MCMC Markov chain
Monte Carlo, GRADE Grading of Recommendations Assessment, Development
and Evaluation
aPriors are based on the detailed methods of prior distribution reported
in IPD-NMAs
bInformal approaches are the comparison of IPD-NMA with meta-regression
IPD-NMA results, comparison of IPD-NMA with aggregate data NMA results,
and comparison of NMA results with pairwise meta-analyses results
cReview Manager was used for pairwise meta-analyses
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Fig. 3 The full compliance rate of each PRISMA-IPD additional item and PRISMA-NMA supplemental item
Fig. 4 The full compliance rate of each item based on AMSTAR-2. RoB, risk of bias
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significant deviations from the protocol, and only one
explained the selection of the study designs for inclusion
in the review. Furthermore, only a few of the included
IPD-NMAs provided a list of excluded studies, assessed
the potential impact of risk of bias (RoB) in individual
studies on the results of the meta-analysis, and inter-
preted the results considered the RoB of primary studies
(Fig. 4).
Stratified analyses found no statistically significant as-
sociations between methodological quality based on the
AMSTAR-2 tool and the general characteristics or statis-
tical methods used in IPD-NMAs, including the industry
funding or not, pre-specified protocol or not, Bayesian
or frequentist method used, and 1-stage or 2-stage
process (Additional file 1: Appendix Table 3). There
were no significant improvements in the methodological
quality of IPD-NMAs after the publication of the
AMSTAR-2 tool (Additional file 1: Appendix Table 4).
Result of correlation analysis
A strong positive correlation was found between the
fully reported PRISMA-IPD items and fully reported
AMSTAR-2 items (Pearson’s ρ = 0.905, P = 0.000) as
shown in Additional file 2: Appendix Fig. 2.
Discussion
Findings and interpretations
This study included 21 IPD-NMAs published between
2007 and 2019, identified from a comprehensive litera-
ture search. We investigated the statistical analysis
methods used and assessed the reporting quality based
on PRISMA-IPD and PRISMA-NMA checklists and
methodological quality using the AMSTAR-2 tool. Over-
all, the reporting of statistical analysis methods was sub-
optimal, and the reporting quality and methodological
quality were low. Compliance rates were insufficient for
most of the items of PRISMA-IPD, PRISMA-NMA, and
AMSTAR-2.
Of the 21 IPD-NMAs, 10 combined both individual
participant data and aggregate data, because IPD were
not available from some relevant trials. We also found
that the Bayesian IPD-NMAs were more likely to use
the 1-stage process, and the Frequentist IPD-NMAs
were more likely to use the 2-stage process. Reluctance
to share data is a major obstacle to obtaining IPD and
performing IPD meta-analysis [36, 37]. A previous study
showed that IPD sharing may depend on study charac-
teristics, including funding type, study size, study risk of
bias, and treatment effect [27]. Of the 21 included IPD-
NMAs, only three mentioned the retrieval bias and none
assessed the impact of the retrieval bias. One of the ad-
vantages of IPD meta-analyses is that it allows the appli-
cation of appropriate multiple imputation techniques to
solve problems related to missing data [3]. However,
only 23.8% of the IPD-NMAs reported the use of statis-
tical techniques to handle missing participant data.
Meta-analyses often have intrinsic heterogeneity, which
can affect the reliability and validity of results [38]. Het-
erogeneity was assessed in 71.4% of the IPD-NMAs, and
the sources of heterogeneity were mostly explored by
performing the subgroup analysis, meta-regression ana-
lysis, or sensitivity analysis. The consistency assumption
is imperative for a valid NMA, and the assessment of in-
consistency should be fully reported in NMAs [24, 33].
However, no more than 45.0% of the IPD-NMAs used
specific methods to evaluate consistency. The transitivity
assumption is another important aspect in NMAs [39],
but none of the included IPD-NMAs assessed the transi-
tivity, which should be given more attention in the fu-
ture work.
For reporting quality based on 31 PRISMA-IPD items
and 5 PRISMA-NMA supplemental items, compliance
rates were above 70.0% for nine items, lower than 40.0%
for 14 items, and lower than 15.0% for 6 items. For IPD
meta-analyses, the importance of checking and correct-
ing any inaccuracies or errors in the IPD is self-evident
[1]. However, more than 60.0% of IPD-NMAs did not
explore data integrity and about 85.7% of IPD-NMAs
did not report data integrity. Therefore, future IPD-
NMAs should clarify which aspects of IPD were subject
to data checking, how data checking was done, and re-
port any important issues identified in checking IPD.
IPD meta-analyses are particularly useful for exploring
the participant-level variation of treatment response [1,
40]. Only about half of the included IPD-NMAs de-
scribed methods for exploring variation in effects by the
study- or participant-level characteristics and stated
participant-level characteristics that were analyzed as po-
tential effect modifiers. About 86.0% of IPD-NMAs did
not present the network of geometry nor did they
summarize the network geometry, which affected the
understanding of NMAs [24, 41]. Furthermore, deficien-
cies were also identified in items related to protocol and
registration, search, study selection, data collection
process, risk of bias in individual studies, results of syn-
theses, risk of bias across studies, and funding.
Of the 16 individual AMSTAR-2 items, only four
items obtained compliance rates higher than 50.0%, and
seven obtained compliance rates lower than 20.0%. Only
4.8% of the IPD-NMAs explained their selection of the
study designs for inclusion in the review, 19.0% provided
a list of excluded studies and justified the exclusions,
and none of the IPD-NMAs reported sources of funding
for the studies included in the review, which is similar to
the findings of other types of SRs and meta-analyses [38,
42, 43]. Therefore, these may be some common meth-
odological shortcomings of any types of SRs. In SRs,
assessing the risk of bias of primary studies and
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investigating publication bias are of great importance as
these will gauge the validity of meta-analytic results,
affect the interpretation of results, and limit our ability
to draw conclusions [43, 44]. Unfortunately, only 28.6%
of IPD-NMAs used a satisfactory technique for assessing
the RoB in individual studies included, and only 19% of
IPD-NMAs assessed the potential impact of RoB on the
results of the meta-analyses. In addition, only 14.3% of
the included IPD-NMAs investigated the publication
bias and discussed its likely impact on the results of the
review. Approximately 30.0% of the IPD-NMAs were
industry-sponsored, and no more than 40.0% of IPD-
NMAs reported potential conflicts of interest and fund-
ing sources, which may lead to potential risks of funding
bias [21]. Publishing protocols can reduce the risk of re-
searcher bias and outcome reporting bias [45–47]. Em-
pirical studies have also found that a priori protocol can
improve the methodological quality of SR [34, 48]. Our
study showed that IPD-NMAs with a priori protocol
tended to have higher methodological quality than IPD-
NMAs without a priori protocol, although the difference
was not statistically significant.
Comparison of our findings with other studies
A previous study found that key methodological and
reporting issues such as consistency assumption, study
protocol, and statistical approaches for missing par-
ticipant data were often insufficiently reported in IPD
indirect comparison studies [3]. These results were
similar to the findings of our analyses of IPD-NMAs.
According to our knowledge, two previous studies
[21, 23] explored the statistical methods, methodo-
logical and reporting characteristics of aggregate data
NMAs. These two empirical studies found that, of the
included NMAs, only 53.0% assessed inconsistency,
56.0% explored heterogeneity, and less than 40.0% in-
vestigated publication bias, which are also similar to
the results of our study. This suggested that IPD-
NMAs and aggregate data NMAs may have the same
defects. Compared with Cochrane NMAs [24], IPD-
NMAs had significantly lower compliance rates in 12
AMSTAR-2 items and 13 PRISMA-NMA items, re-
vealing that both the methodological and reporting
quality of IPD-NMAs were lower than Cochrane
NMAs. Therefore, there was room for further im-
provement in both Cochrane NMAs and IPD-NMAs,
such as the geometry of the network, the risk of bias
in individual studies, and the assessment of
inconsistency.
Strengths and limitations
This is the first comprehensive evaluation of published
IPD-NMAs, in terms of statistical methods used, report-
ing quality based on PRISMA-IPD and PRISMA-NMA
checklists, and methodological quality based on the
AMSTAR-2 tool. Furthermore, we also conducted
stratified analyses to explore potential factors that
may affect the reporting and methodological quality
and further performed the correlation analysis to
evaluate whether the reporting quality was relevant to
the methodological quality. However, our study also
has some limitations. First, the number of IPD-NMAs
included in our study was small, although we have
identified all available IPD-NMAs by conducting a
comprehensive literature search. Second, our data
depended on the information reported in the included
IPD-NMAs, so we could not rule out the possibility
that some important methods were appropriately used
in the study but not reported [3]. Third, we mainly
focused on the impact of selected factors on the
methodological and reporting quality of IPD-NMAs.
Finally, we included a very small number of IPD-
NMAs and conducted a large number of statistical
tests. Any significant results of stratified analyses
should be interpreted with caution.
Implications for further research and practice
Our study indicated that the reporting and methodo-
logical quality of IPD-NMAs needs to be further im-
proved. The identified drawbacks need to be addressed,
and future IPD-NMAs should be conducted according
to reporting and methodological guidelines [1, 33, 35].
In this study, we assessed the reporting quality of IPD-
NMAs using PRISMA-IPD and PRISMA-NMA state-
ments. However, the PRISMA-IPD statement aims to
improve the reporting quality of SRs and meta-analyses
of IPD, while the PRISMA-NMA aims to improve the
completeness and transparency of reporting of NMAs.
Currently, there are no reporting standards aimed to
enhance the reporting of IPD-NMAs. Therefore, it is
necessary to develop a reporting quality tool for IPD-
NMAs, incorporating relevant items from both
PRISMA-IPD and PRISMA-NMA. For example, the re-
port should be identified as a network meta-analysis of
individual participant data in the title; describe methods
used to explore the network geometry, transitivity as-
sumption, and consistency assumption; and describe
statistical techniques used for missing participant data
and methods used to explore variation in effects.
Conclusions
The key information on statistical methods was often
missing, and compliance rates of reporting and meth-
odological items were suboptimal in published IPD-
NMAs. Methodological and reporting shortcomings
include handling of missing participant data, assess-
ment of publication bias, clarification of the IPD in-
tegrity, description of network geometry, and
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assessment of the consistency. Authors of future IPD-
NMAs should address the identified flaws and strictly
adhere to methodological and reporting guidelines.
We recommend the development of a reporting qual-
ity tool that is specifically applicable to IPD-NMAs.
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